Section of Endocrinology & Investigative Medicine, Imperial College London, London, UK; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Section of Endocrinology & Investigative Medicine, Imperial College London, London, UK; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Cell. 2023 Aug 3;186(16):3332-3332.e1. doi: 10.1016/j.cell.2023.07.011.
Menopausal hot flashes are common and debilitating. Menopausal Hormone Therapy (MHT) is effective for hot flashes but has risks and side effects that limit its use. NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes. To view this Bench to Bedside, open or download the PDF.
绝经相关热潮红很常见且令人不适。激素治疗（MHT）对热潮红有效，但存在风险和副作用，限制了其应用。NK3 受体拮抗剂已成为一种新的治疗策略，最近 FDA 批准了 fezolinetant，这是一种用于治疗绝经相关热潮红的首创非激素类药物。要查看本从临床前到临床转化研究，可打开或下载 PDF。
